These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 30041175)
21. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs. Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. Irwin N; McClean PL; Flatt PR J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662 [TBL] [Abstract][Full Text] [Related]
23. Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes. Brill AL; Wisinski JA; Cadena MT; Thompson MF; Fenske RJ; Brar HK; Schaid MD; Pasker RL; Kimple ME Mol Endocrinol; 2016 May; 30(5):543-56. PubMed ID: 27049466 [TBL] [Abstract][Full Text] [Related]
24. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. Moritoh Y; Takeuchi K; Hazama M J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898 [TBL] [Abstract][Full Text] [Related]
25. Stapled and Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843 [TBL] [Abstract][Full Text] [Related]
26. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Akarte AS; Srinivasan BP; Gandhi S Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634 [TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells. Ma X; Guan Y; Hua X J Diabetes; 2014 Sep; 6(5):394-402. PubMed ID: 24725840 [TBL] [Abstract][Full Text] [Related]
28. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro. Shao W; Wang Z; Ip W; Chiang YT; Xiong X; Chai T; Xu C; Wang Q; Jin T Am J Physiol Endocrinol Metab; 2013 Jun; 304(12):E1263-72. PubMed ID: 23571712 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919 [TBL] [Abstract][Full Text] [Related]
30. Coumaglutide, a novel long-acting GLP-1 analog, inhibits β-cell apoptosis in vitro and invokes sustained glycemic control in vivo. Sun L; Wang C; Dai Y; Chu Y; Han J; Zhou J; Cai X; Huang W; Qian H Eur J Pharmacol; 2015 Nov; 767():211-9. PubMed ID: 26481165 [TBL] [Abstract][Full Text] [Related]
31. Role of β Cell Precursors in the Regeneration of Insulin-Producing Pancreatic β Cells under the Influence of Glucagon-Like Peptide 1. Skurikhin EG; Pakhomova AV; Epanchintsev AA; Stronin OV; Ermakova NN; Pershina OV; Ermolaeva LA; Krupin VA; Kudryashova AI; Zhdanov VV; Dygai AM Bull Exp Biol Med; 2018 Sep; 165(5):644-648. PubMed ID: 30225696 [TBL] [Abstract][Full Text] [Related]
35. Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling. Yang L; Yao D; Yang H; Wei Y; Peng Y; Ding Y; Shu L Mol Endocrinol; 2016 Mar; 30(3):361-71. PubMed ID: 26789107 [TBL] [Abstract][Full Text] [Related]
36. Flavone Hispidulin Stimulates Glucagon-Like Peptide-1 Secretion and Ameliorates Hyperglycemia in Streptozotocin-Induced Diabetic Mice. Wang Y; Wang A; Alkhalidy H; Luo J; Moomaw E; Neilson AP; Liu D Mol Nutr Food Res; 2020 Mar; 64(6):e1900978. PubMed ID: 31967385 [TBL] [Abstract][Full Text] [Related]
37. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944 [TBL] [Abstract][Full Text] [Related]
38. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]
39. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice. O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756 [TBL] [Abstract][Full Text] [Related]
40. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus]. Escalada FJ Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]